Vancomycin Market Report 2026

The vancomycin market size has grown rapidly in recent years. It will grow from $0.91 billion in 2025 to $1.01 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rising prevalence of gram-positive bacterial infections, increased hospital admission rates, early adoption of vancomycin as last-resort therapy, expansion of intensive care infrastructure, growing incidence of antibiotic resistance.

The vancomycin market size is expected to see strong growth in the next few years. It will grow to $1.46 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for advanced injectable antibiotics, rising focus on infection prevention protocols, expansion of hospital pharmacy automation, growing investments in antimicrobial research, enhanced regulatory oversight on antibiotic usage. Major trends in the forecast period include increasing demand for glycopeptide antibiotics, rising focus on hospital-acquired infection management, expansion of ready-to-use injectable formulations, growing emphasis on antimicrobial stewardship programs, enhanced monitoring of drug resistance patterns.

The growing incidence of infectious diseases is anticipated to drive expansion in the vancomycin market in the coming years. Infectious diseases are conditions caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, and include illnesses like influenza, tuberculosis, malaria, HIV/AIDS, and COVID-19. The rise in these diseases is linked to factors such as increasing antimicrobial resistance, climate change, and global population growth. Vancomycin plays a critical role in the treatment of serious gram-positive bacterial infections, particularly those caused by resistant strains, with its use guided by clinical protocols and antimicrobial stewardship to ensure effective patient outcomes. For **instance**, in October 2024, the World Health Organization, a Switzerland-based global public health body, reported that around 8.2 million people were newly diagnosed with tuberculosis in 2023, an increase from approximately 7.5 million in 2022, making tuberculosis the deadliest infectious disease worldwide. **Therefore**, the increasing burden of infectious diseases is fueling growth in the vancomycin market.

Major players in the vancomycin market are concentrating on the development of innovative offerings, including anti-infective and anti-hypotensive drugs, to maintain their competitive position. Anti-infective drugs are used to treat infections caused by bacteria, viruses, fungi, parasites, or other microorganisms, while anti-hypotensive drugs are intended to elevate blood pressure in patients with hypotension. For instance, in April 2024, Baxter International Inc., a US-based healthcare company, announced the introduction of five injectable products in the United States as part of its continued expansion of its pharmaceutical portfolio. These injectable products are designed to meet specific clinical needs, with advancements spanning anesthesia, pain management, and specialized therapeutic areas, underscoring the company’s focus on equipping healthcare professionals with effective tools to enhance patient care.

In January 2023, Fairlong Capital LLC, a US-based investment firm, acquired the DoseMeRx business from Tabula Rasa HealthCare Group Inc. for an undisclosed sum. Through this acquisition, Fairlong Capital LLC seeks to broaden its presence in the healthcare technology space by leveraging DoseMeRx’s capabilities in clinical decision support software for individualized dosing. DoseMeRx is an advanced solution that enables precise dosing of high-risk parenteral medications, supporting pharmacists and physicians in customizing doses based on individual patient needs. Tabula Rasa HealthCare Group Inc. is a US-based company that supplies vancomycin injections.

Major companies operating in the vancomycin market are ANI Pharmaceuticals Inc., Alvogen Inc., Xellia Pharmaceuticals ApS, Sagent Pharmaceuticals, Fresenius Kabi AG, Lupin Limited, Eugia Pharma Specialities, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, Slate Run Pharmaceuticals, Alkem Laboratories Ltd., Azurity Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi SA, Bayer AG, GlaxoSmithKline plc, Merck & Co Inc., Aurobindo Pharma Limited, Cipla Inc., Johnson & Johnson, Bristol‑Myers Squibb Company, AbbVie Inc., Janssen Global, Shenwei Pharmaceutical Hainan Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Sun Pharmaceutical Industries Ltd., Viatris Inc., North China Pharmaceutical Group, Taiwan Zhengde Pharmaceutical, LegoChem Biosciences, Nabriva Therapeutics, MicuRx Pharmaceuticals, MGB Biopharma Limited, VIANEX.

North America was the largest region in the vancomycin market in 2025. The regions covered in the vancomycin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vancomycin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the vancomycin market by increasing costs of imported active pharmaceutical ingredients, fermentation inputs, sterile packaging materials, and manufacturing equipment used in injectable and oral formulations. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on imported raw materials, while Asia-Pacific faces pricing pressure on generic exports. These tariffs are increasing production costs and affecting supply stability. However, they are also encouraging domestic API production, localized pharmaceutical manufacturing, and investment in resilient antibiotic supply chains.

The vancomycin market research report is one of a series of new reports that provides vancomycin market statistics, including vancomycin industry global market size, regional shares, competitors with a vancomycin market share, detailed vancomycin market segments, market trends and opportunities, and any further data you may need to thrive in the vancomycin industry. This vancomycin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vancomycin is a powerful antibiotic used to treat infections caused by bacteria. It is part of the glycopeptide class of antibiotics and is especially effective against Gram-positive bacteria, including strains that are resistant to other antibiotics. Vancomycin acts by blocking bacterial cell wall synthesis, which stops the bacteria from growing and reproducing.

The main forms of vancomycin include injectable solutions and powder for injection. Injectable vancomycin is available as pre-mixed liquid preparations designed for intravenous use. These formulations allow the medication to be delivered directly into the bloodstream, providing rapid and effective treatment for serious infections. Vancomycin can be administered intravenously or orally and is used for conditions such as sepsis, lung infections, skin and soft tissue infections, colitis and intestinal inflammation, as well as for infection prevention.

The vancomycin market consists of sales of intravenous (IV) formulations, compounded products, diagnostic kits and monitoring devices, therapeutic drug monitoring (TDM) kits, and diagnostic devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.